Article Figures & Data
Figures
- Figure 1
Kaplan-Meier analysis of MACEs based on the ApoA-I levels. The 294 patients were divided by tertiles of the ApoA-I levels: 0.99, 0.99–1.14, and >1.14 g/L. Risk of a MACE increased with decreasing tertile of the ApoA-I levels (log-rank test 33.354, p<0.001). ApoA-I, apolipoprotein A-I; MACE, major adverse cardiovascular event.
Tables
- Table 1
Baseline characteristics of the first group
Characteristics Grouped by LVEF (%) P value Grouped by log NT-proBNP (pg/mL) P value <40 (n=47) 40–50 (n=79) >50 (n=377) <6.82 (n=140) 6.82–9.06 (n=142) >9.06 (n=139) Age (years) 66.21±12.71 66.58±12.88 66.46±11.94 ns 68.07±12.23 66.13±11.23 65.09±13.33 ns Male, n (%) 36 (76.60) 61 (77.22) 245 (64.99) ns 86 (61.42) 99 (69.71) 104 (74.82) ns Height (cm) 171.39±5.74 169.13±5.94 168.88±7.40 ns 168.41±7.461 168.46±7.59 170.58±5.59 ns Weight (kg) 74.30±9.74 71.22±10.44 69.20±10.75 ns 67.32±10.76 69.59±11.19 73.10±9.52 <0.05 Heart rate (beats/min) 84.43±19.92 77.19±16.06 72.86±12.26 <0.001 71.37±9.54 73.14±13.91 78.26±17.36 <0.001 ALT (U/L) 49.61 (18.85–37.50) 53.25 (24.00–75.20) 29.94 (18.00–36.00) ns 27.41 (17.25–32.00) 29.27 (19.00–34.00) 42.72 (21.00–46.00) <0.05 AST (U/L) 113.48 (23.45–83.25) 165.91 (37.00–293.60) 54.24 (21.00–50.50) ns 37.54 (20.50–27.50) 76.35 (21.50–71.75) 89.42 (24.00–113.00) <0.05 BUN (mmol/L) 11.19 (5.46–15.58) 5.20 (4.10–6.45) 5.44 (4.15–6.71) ns 4.98 (3.83–6.21) 5.75 (4.43–6.79) 6.03 (4.44–6.79) ns Creatine (µmol/L) 167.71 (81.70–163.50) 82.57 (63.00–97.00) 82.75 (69.90–92.75) ns 77.80 (67.00–89.20) 87.89 (73.75–94.95) 96.12 (75.60–101.00) <0.001 UA (µmol/L) 411.47 (337.75–397.03) 322.89 (264.48–403.97) 323.92 (258.64–386.10) ns 305.34 (251.27–367.80) 326.44 (245.53–403.67) 329.70 (272.30–369.20) ns Serum lipid profile TG (mmol/L) 1.37±0.71 1.78±1.29 1.78±1.17 ns 1.90±1.34 1.81±1.18 1.45±0.81 <0.05 TC (mmol/L) 3.80±1.14 4.02±0.87 3.93±0.92 ns 3.97±0.87 3.91±0.92 3.97±1.01 ns HDL-C (mmol/L) 0.90±0.27 0.93±0.22 0.95±0.54 ns 0.96±0.23 0.93±0.25 0.95±0.24 ns LDL-C (mmol/L) 2.73±3.26 2.43±0.71 2.35±0.77 ns 2.36±0.70 2.35±0.78 2.40±0.85 ns non-HDL (mmol/L) 3.75±5.76 4.37±11.37 2.94±0.98 ns 3.00±0.79 2.96±0.88 3.02±0.94 ns LDL/HDL 2.82±1.76 2.72±0.98 2.56±1.02 ns 2.52±0.79 2.62±1.01 2.63±1.07 ns ApoA-I (g/L) 1.02±0.24 1.04±0.17 1.11±0.19 <0.05 1.11±0.18 1.10±0.19 1.04±0.20 <0.05 HDL/ApoA-I (mmol/g) 0.88±0.13 0.89±0.13 0.85±0.15 ns 0.86±0.19 0.84±0.12 0.90±0.12 <0.05 Data are mean±SD and number (%).
ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; ApoA-I, apolipoprotein A-I; AST, aspartate aminotransferase; BUN, blood urea nitrogen; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; ns, not significant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TC, total cholesterol; TG, triglyceride; UA, uric acid.
- Table 2
Correlation between serum lipid profile and cardiac function in patients with acute myocardial infarction in the first group
Characteristics LVEF Log NT-proBNP Pearson correlation Sig. (two-tailed) N Pearson correlation Sig. (two-tailed) N TG (mmol/L) 0.088 ns 471 −0.171 <0.05 402 TC (mmol/L) −0.023 ns 469 −0.02 ns 399 HDL-C (mmol/L) 0.081 ns 470 −0.037 ns 401 LDL-C (mmol/L) −0.031 ns 470 0.008 ns 401 Non-HDL (mmol/L) −0.051 ns 467 −0.009 ns 398 LDL/HDL −0.07 ns 470 0.04 ns 401 ApoA-I (g/L) 0.165 <0.001 469 −0.181 <0.001 400 HDL-C/ApoA-I (mmol/g) 0.039 ns 471 0.14 <0.05 400 ApoA-I, apolipoprotein A-I; ApoA-I, apolipoprotein A-I; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; ns, not significant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TC, total cholesterol; TG, triglyceride.
- Table 3
Baseline characteristics of the second group
Characteristics Grouped by LVEF (%) P value Grouped by log NT-proBNP (pg/mL) P value <40 (n=23) 40–50 (n=58) >50 (n=193) <7.51 (n=95) 7.51–9.58 (n=91) >9.58 (n=93) Age (years) 59.52±12.14 62.48±11.86 59.93±10.18 ns 57.84±10.46 60.47±9.73 63.34±11.70 ns Male, n (%) 22 (95.65) 49 (84.48) 141 (73.05) ns 68 (71.57) 67 (73.62) 80 (86.02) ns Height (cm) 171.44±6.60 169.10±7.63 167.80±7.16 ns 168.43±7.67 168.33±7.09 168.40±7.22 ns Weight (kg) 74.03±11.25 72.54±10.47 70.39±11.45 ns 71.37±11.27 71.36±12.23 70.06±10.70 ns Heart rate (beats/min) 80.13±17.96 71.45±13.36 69.05±11.45 <0.001 68.49±11.90 68.67±10.81 74.62±14.60 <0.001 ALT (U/L) 38.71 (18.65–52.50) 43.99 (20.05–51.50) 36.52 (20.05–51.50) ns 36.35 (17.00–38.80) 37.71 (17.94–50.30) 39.14 (16.90–52.50) ns AST (U/L) 77.09 (18.30–61.62) 90.32 (20.07–123.05) 48.69 (18.57–57.28) <0.05 41.65 (17.34–36.61) 54.35 (20.54–62.33) 77.36 (19.89–103.46) <0.001 BUN (mmol/L) 5.42 (4.30–6.37) 5.43 (4.45–6.05) 4.64 (3.69–5.34) <0.001 4.69 (3.90–5.36) 4.83 (3.80–5.49) 5.24 (4.05–5.93) <0.05 Creatine (µmol/L) 76.68 (63.17–81.05) 78.29 (64.05–85.73) 66.43 (57.16–74.18) <0.05 64.80 (57.94–71.36) 67.49 (56.92–76.32) 76.81 (62.00–82.07) <0.05 UA (µmol/L) 351.34 (277.55–414.69) 318.94 (261.01–380.00) 311.31 (255.64–349.03) <0.05 315.48 (252.16–352.48) 306.18 (248.97–348.78) 325.11 (266.83–375.34) ns Serum lipid profile TG (mmol/L) 1.60±1.45 1.46±0.87 1.66±0.89 ns 1.77±0.90 1.74±1.16 1.36±0.69 ns TC (mmol/L) 4.02±1.04 3.51±0.89 3.82±0.80 ns 3.77±0.81 3.71±0.80 3.88±1.00 ns HDL-C (mmol/L) 0.88±0.26 0.91±0.24 0.92±0.21 ns 0.93±0.24 0.92±0.20 0.88±0.23 ns LDL-C (mmol/L) 2.23±0.95 2.02±0.73 2.30±0.81 ns 2.25±0.77 2.30±0.84 2.13±0.84 ns Non-HDL (mmol/L) 3.10±0.98 2.63±0.82 2.90±0.76 ns 2.82±0.79 2.80±0.76 2.97±0.93 ns LDL/HDL 2.60±0.90 2.31±0.89 2.60±1.02 ns 2.56±1.07 2.55±0.89 2.51±1.03 ns ApoA-I (g/L) 1.00±0.23 1.06±0.20 1.08±0.18 ns 1.11±0.20 1.08±0.16 1.00±0.19 <0.001 HDL/ApoA-I (mmol/g) 0.87±0.12 0.86±0.11 0.84±0.10 ns 0.83±0.96 0.84±0.10 0.87±0.11 <0.05 Data are mean±SD and number (%).
ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; ApoA-I, apolipoprotein A-I; AST, aspartate aminotransferase; BUN, blood urea nitrogen; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; ns, not significant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TC, total cholesterol; TG, triglyceride; UA, uric acid.
- Table 4
Correlation between serum lipid profile and cardiac function in patients with acute myocardial infarction in the second group
Characteristics LVEF Log NT-proBNP Pearson correlation Sig. (two-tailed) N Pearson correlation Sig. (two-tailed) N TG (mmol/L) 0.035 ns 271 −0.175 <0.001 277 TC (mmol/L) 0.093 ns 169 −0.01 ns 165 HDL-C (mmol/L) 0.111 ns 271 −0.085 ns 277 LDL-C (mmol/L) 0.100 ns 271 −0.08 ns 277 Non-HDL (mmol/L) 0.076 ns 169 0.01 ns 165 LDL/HDL 0.036 ns 271 −0.03 ns 277 ApoA-I (g/L) 0.165 <0.05 271 −0.23 <0.001 277 HDL-C/ApoA-I (mmol/g) −0.028 ns 271 0.181 <0.05 277 ApoA-I, apolipoprotein A-I; ApoA-I, apolipoprotein A-I; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; ns, not significant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TC, total cholesterol; TG, triglyceride.
- Table 5
Univariate and multivariate Cox analysis for MACEs in the second group
Variable Univariate analysis Multivariate analysis HR 95% CI P value HR 95% CI P value ApoA-I levels High (>1.14 g/L) Reference Reference Middle (0.99–1.14 g/L) 1.484 0.713 to 3.091 0.291 1.734 0.649 to 4.631 0.272 Low (<0.99 g/L) 2.294 1.239 to 4.248 0.008 3.411 1.373 to 8.665 0.008 Adjusted for age, sex, height, weight, creatinine, left ventricular ejection fraction, and N-terminal pro-B-type natriuretic peptide.
ApoA-I, apolipoprotein A-I; 95 % CI, 95 % confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event.
